Persistent Multidrug-Resistant Salmonella enterica Serovar Paratyphi A Bacteremia in a Preterm Neonate: A Case Report
Abstract
Background: Neonatal sepsis caused by Salmonella enterica serovar Paratyphi A is rare and may present with nonspecific clinical features. Multidrug-resistant strains pose substantial diagnostic and therapeutic challenges, particularly in resource-limited settings.
Case presentation: We report a preterm neonate born at 33 weeks of gestation with a birth weight of 1800 g who initially presented with respiratory distress and was managed as transient tachypnea of the newborn. The infant subsequently developed persistent fever, feeding intolerance, abdominal distension, leukopenia, severe thrombocytopenia, and elevated inflammatory markers despite initially negative blood cultures. A blood culture obtained on Day 20 of life grew multidrug-resistant S. Paratyphi A, resistant to ceftriaxone, ciprofloxacin, pefloxacin, and trimethoprim-sulfamethoxazole, with intermediate susceptibility to amikacin. The infant required blood-product support and prolonged antimicrobial therapy. A 21-day course of empiric cefoperazone/sulbactam plus levofloxacin was administered with close monitoring and was temporally associated with clinical improvement and microbiological clearance. Blood cultures obtained on Days 45 and 50 were negative. No maternal or apparent healthcare-associated source was identified.
Conclusion: Persistent multidrug-resistant S. Paratyphi A bacteremia should be considered in neonates with refractory sepsis despite initially negative blood cultures. Repeated cultures,…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.